BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 5, 2018
View Archived Issues
Biogen and AbbVie voluntarily withdraw Zinbryta worldwide
Read More
Ethics committee approves phase I study of cancer vaccine BIL-06v
Read More
Researchers present phase I data for norovirus vaccine VXA-G1.1-NN
Read More
Novel human insulin analogues created at Jiangsu Hengrui Medicine
Read More
Dosing begins in first in human trial of CPX-POM in patients with advanced solid tumors
Read More
AureoGen Biosciences descibes new aureobasidin A derivatives
Read More
Merck KGaA divulges novel BTK inhibitors
Read More
Novel muscarinic acetylcholine M4 receptor PAMs patented by Vanderbilt University
Read More
Marine compound conjugated to trastuzumab is active against HER2+ tumors
Read More
Moogene Medi describes DPP4-targeting cas9 protein and guide RNAs
Read More
FDA accepts NDA for Jazz Pharmaceuticals' solriamfetol
Read More
Gene therapy from Meiragtx receives European PRIME disgnation
Read More
CARB-X supports Macrolide's development of macrolide antibiotics with Gram-negative activity
Read More
Santhera reports findings from phase I/II trial of idebenone in primary progressive MS
Read More
FDA approves Otonomy's Otiprio for acute otitis externa
Read More
New phase I trial explores use of HB002.1M in neovascular AMD
Read More
CYP11A1 expression identifies anaphylaxis risk in children with peanut allergy
Read More
HEC Pharm's HBV capsid inhibitor HEC-72702 shows promise for further development
Read More
DCIR found as potential therapeutic target for atopic dermatitis
Read More
Idera initiates phase III study of IMO-2125 with ipilimumab for refractory melanoma
Read More
Max Planck Gesellschaft and Arsanis Biosciences synthesize antibodies targeting K. pneumoniae LPS
Read More